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In the confocal mode, Raman microspectroscopy can profile the biochemical content of biological cells at a
subcellular level, and any changes to it by exogenous agents, such as therapeutic drugs or toxicants. As an exploration
of the potential of the technique as a high content, label free analysis technique, this report reviews work to monitor
the spectroscopic signatures associated with the uptake and response pathways of commercial chemotherapeutic
agents and polymeric nanoparticles by human lung cells. It is demonstrated that the signatures are reproducible and
characteristic of the cellular event, and can be used, for example, to identify the mode of action of the agent as well
as the subsequent cell death pathway, and even mechanisms of cellular resistance. Data mining approaches are
discussed and a spectralomics approach is proposed.
OCIS codes: (170.5660) Raman spectroscopy, (180.5655) Raman microscopy, (170.1530) Cell analysis, (170.1580) Chemometrics.
http://dx.doi.org/10.1364/AO.99.099999

1. INTRODUCTION
The application of Raman spectroscopy to biomolecules and
even tissues was first demonstrated as early as the 1960s[1-3]
and by the mid-1970s biomedical applications were explored[4].
Whole cell and tissue studies have been carried out on a range of
pathologies[5-9] and in vivo studies[10-12] have demonstrated
the prospective for diagnostic applications. The potential of
vibrational spectroscopy in conjunction with multivariate
analysis techniques as a diagnostic tool has thus been well
demonstrated and the concept of Spectral Cytopathology has
been coined[13]. However, since the original claims in the 1990s,
clinical translation has been slow, potentially due to demands of
large scale clinically relevant studies and the rigours of
legislative approval, prompting an appraisal of more realistic
strategically achievable targets for the field[14]. Importantly, the
intrinsic strength of spectroscopy is in materials and process
analysis rather than classification, and in vitro studies of cells
allow a detailed analysis of the fundamental cell biology, or
biochemical changes, for example as a result of an external
agonist, toxicant or chemotherapeutic agent[15-17]. The
technique is label free, and, in the case of Raman

microspectroscopy, subcellular analysis can be performed in the
confocal microscopic mode, providing high content
spectroscopic signatures of biochemical profiles, promising
potentially more realisable applications in fundamental cellular
(cytological)
research,
medicinal
chemistry
and
pharmacological/toxicological
screening.
Regulatory
requirements in both the EU and US (EU Directive-2010/63/EU
and US Public Law 106-545, 2010, 106th Congress) have
increasingly restricted the use of animal models for
development of pharmaceuticals and cosmetics, and Raman
microspectroscopy offers a potentially low cost, label free
alternative to in vitro High Content Analysis for routine
screening.[18, 19]
This paper reviews recent work carried out at the Dublin
Institute of Technology, to advance Raman microspectroscopy
for cellular and subcellular analysis, probing the limitations of
the technique in terms of reproducibility and specificity of
spectral signatures of subcellular events and pathways.
Specifically, it explores the areas of (A) Cellular differentiation
(B) Drug screening and (C) Nanotoxicological screening. As
models, the responses elicited by established and commercially
available chemotherapeutic agents and nanoparticle standards
in commercially available in vitro cell lines are chosen. The often

subtle spectroscopic changes associated with the cellular
perturbations are elucidated using a range of multivariate data
mining techniques, and the challenge of identifying consistent
reproducible label free spectral markers is addressed.

2. EXPERIMENTAL
The details of experimental methods and protocols are described in
the original publications[20-23], but are summarised here.
A. Materials
A549 human lung adenocarcinoma cells with the alveolar type II
phenotype were obtained from ATTC (Manassas, VA, USA) and Calu-1
human lung epidermoid carcinoma cells were obtained from the
European Collection of Cell Cultures.
Doxorubicin hydrochloride® powder (Sigma Life Sciences, Ireland)
was diluted in 1mL sterile water to the required concentration,
identified by cytotoxicological assays.
40 nm non-toxic carboxyl-modified polystyrene nanoparticles
(PSNPs) were employed to determine nanoparticle localisation and
trafficking, whereas 100 nm toxic amine-modified polystyrene
nanoparticles (PS-NH2) were used to determine spectral markers of the
toxicity. Generation 5 PAMAM dendrimers were used as a secondary
toxic nanoparticle model for comparison of spectral markers of toxicity.
All nanomaterials were purchased from Sigma-Aldrich (Ireland).
B. Cell Culture
A549 cells were cultured in DMEM (with 2 mM L-glutamine) with
10 % foetal bovine serum (FBS) and Calu-1 cells in RPMI with 10% FBS,
both at 37°C in a humidified atmosphere containing 5% CO2 and cells
were split every two days to maintain ~60% confluence.
C. Raman Microspectroscopy
Cells (~ 3 x 103/cm2) were seeded and incubated on (20mm
diameter) CaF2 windows (Crystan Ltd, UK) for 24 hrs for both control
and exposure to chemotherapeutic drug or nanoparticles. Medium was
then removed and samples were rinsed twice with sterile PBS and
covered with solutions of the appropriate drug solution or nanoparticle
suspension concentration. After each incubation period cells were
washed twice with sterile PBS and fixed in formalin (10 %, 15 min).
A Horiba Jobin-Yvon LabRAM HR800 spectrometer with a 785 nm,
300 mW diode laser as source, Peltier cooled 16-bit CCD, 300 lines/mm
grating and 100 μm confocal hole, was used for this work. Cells were
measured either air dried or in water immersion, and spectra were
acquired from the three cell locations: cytoplasm, nuclear and nucleolar
in the range from 400 cm-1 to 1800 cm-1 with an x100 objective
(LCPlanN, Olympus (dry), or LUMPlanF1, Olympus (immersion)) for 30
s two times, to finally produce a data set of 30 points per cell location for
each cell line, over a total of 90 different cells.
D. Data Processing and Analysis
Raman spectral pre-processing and analysis were performed in
Matlab using algorithms developed in house. Prior to analysis,
background was subtracted using a NCLS (non-negatively constrained
least squares) algorithm, spectra were smoothed (Savitsky-Golay filter
3th order, 11 points), baseline corrected (fifth order polynomial) and
vector normalised.

Principal components analysis (PCA) was employed as an
unsupervised multivariate approach to analyse data and the effects of
the drug or nanoparticles in each cell localisation. The order of the PCs
denotes their importance to the dataset and PC1 describes the highest
amount of variation.
Partial least squares regression (PLSR), a statistical regression
technique which reduces the dimensionality of the data and correlates
information, here represented by the Raman spectra, to values of the
drug concentration inside the cells, and the time evolution, was
employed to track the temporal and dose dependent evolution of the
spectral signatures in the subcellular regions. The percentage of
variance explained as a function of the number of components was
calculated using 10-fold cross validation and from a plot of the percent
of variance explained as a function of number of components, the
majority percentage of variance (above 90%) was found to be explained
by the first 3 components.
The regression coefficients obtained by PLSR of Raman data
regressed separately against drug cellular concentration and time
evolutions were plotted and analysed. As a function of frequency, the coefficients illustrate the spectral features which are influenced by the
intracellular interaction of the drug and the resulting metabolic changes.

3. Results
A. Cellular differentiation
Raman spectra were taken from the three cellular regions for all cell
lines and Figure 1 shows the average spectra corresponding to each cell
region, for the example of A549 cells [20]. Visibly, it can be seen that the
mean spectra of the nucleolar, nuclear and cytoplasmic regions are
somewhat different, and discriminating peaks (indicated by highlighted
regions in Figure 1) at, for example, 1578, 1095, 830 and 795 cm-1 can
be assigned to nucleic acids, corresponding respectively to vibrations of
the DNA bases adenine and guanine, DNA PO2- symmetric stretching,
ribose phosphate and DNA backbone O-P-O stretching, [24, 25] while
others at 1300 (CH deformation) and 717 cm-1 (CN+(CH3)3 stretching)
are associated with lipid components of the cell membrane, which are
also observable in the spectra of the nuclear and nucleolar regions,
although more prominently in the spectra of the cytoplasmic region.
The DNA bands at 1095 cm-1 and 830 cm-1 indicate that the DNA is in
the B form, while the peak at 813 cm-1 corresponds to DNA A form.[26]

Fig. 1. Mean spectra of A. Nucleolus, B. Nucleus and C. Cytoplasm
of A549 cell line. Highlighted regions correspond to DNA/RNA
and lipids features.[20]
For a more detailed understanding of the differences in
spectral profiles of the subcellular regions, a multivariate
analysis is more informative, and therefore, PCA was employed
to analyse and compare the spectral profiles of the subcellular

regions as well as the differences between cancer and normal
cell lines. Figure 2 shows the PCA scatter plot of the cytoplasmic,
nuclear and nucleolar spectra of the Calu-1 cell line, along with
the corresponding loadings of PC1 and PC2. PC1 clearly
differentiates between the cytoplasmic and integrated nuclear
regions (nuclear and nucleolar) and, according to the
corresponding loading (loading 1), the most visible discriminant
features derive from DNA, 795 cm-1 and 1095 cm-1, related to BDNA O-P-O backbone stretching and PO2- symmetric stretching,
and lipids at 717 (CN+(CH3)3 stretching), 1300 (CH2 stretching)
and 1440 cm-1 (CH stretching). The differentiation of the
subcellular regions according to PC1 is not unexpected, due to
the significant biochemical differences between the combined

nuclear and cytoplasmic regions which are similar for all cell
lines. The nuclear and nulceolar regions can be differentiated by
a further, pairwaise PCA of the two subcellular regions.[20]
Notably, a similar differentiation between the subcellular
regions of A549 cells can be performed, and the differentiating
PC loadings are almost identical to those of Calu-1 (Figure 2C).
In fact, although they are relatively well distinguished from
normal cell lines, differentiation between cancer cell lines is only
achievable by comparison of the nucleolar regions.[22]
Critically, the similarities of the differentiating subcellular
spectral profiles for different cell lines supports the consistency
and robustness of the technique for subcellular analysis.

Fig. 2. PCA of nucleolus, nucleus and cytoplasm in immersion conditions A. Calu-1 cell line : Cytoplasm Nucleus Nucleolus B. Calu1 differentiating PC loadings C. A549 differentiating PC loadings [20]
cardiomyopathy.[35, 40-42] DNA remains the main target of
cancer therapeutics, whereby induction of DNA damage initiates
B. Drug screening
a cascade of events that determines cellular apoptosis. DNA
damage level and repair, by expression of anti-apoptotic
Raman microspectroscopy has attracted considerable
proteins such as bcl-2 and resistance to apoptosis, are the main
attention over the last few years in the pharmaceutical field to
processes involved in carcinogenesis and in the response of
aid in areas such as the drug discovery process, quality control
cancer cells to cancer chemotherapy.[43]
during industrial manufacturing and detection of counterfeit
products,[27-29] as well as its possible clinical applications.[30,
31] Its potential as a screening technique either for normal and
cancer cell discrimination or in chemotherapeutic and cellular
process screening has been demonstrated.[32]
Doxorubicin (DOX), a non cell cycle specific
chemotherapeutic agent, is one of the two first anthracycline
antibiotics isolated from Streptomyces peucetius[33] and
among the most widely used chemotherapeutic agents, despite
its numerous side effects,[34, 35] and is highly effective in
treating different types of cancers, from leukaemia, thyroid, and
lung to many other neoplasia, especially metastatic and invasive
ones.[36-38] The accepted mechanisms of action of DOX are
complex and not fully understood. They include interactions
within the cell nucleus, consisting of DNA intercalation, crosslinking, binding and alkylation, inhibition of topoisomerase I and
II and RNA polymerase, all inducing DNA damage, inhibition of
DNA replication and protein synthesis (rRNA transcription
inhibition), as a consequence, leading to nucleolar disruption
and cellular apoptosis[39]. DOX also interacts with the cell
membrane and mitochondria, resulting in generation of reactive
oxygen species leading to direct membrane damage and
oxidative stress, responsible for the major DOX side effect,

A.

B.

Fig. 3. A. Structure of Doxorubicin B. Raman spectrum of in
aqueous solution indicating strong DOX marker bands.[21]
To demonstrate the potential of Raman microspectroscopy
to monitor the uptake of chemotherapeutic agents, to track the
drug pathway and monitor cellular responses, Raman profiles
from the three subcellular compartments, nucleolus, nucleus
and cytoplasm, were analysed as a function of time after
exposure of cell cultures to DOX sulutions. The anthracycline
structure of DOX (Figure 3A), consisting of a conjugated
anthraquinone ring structure banded to an aminoglycoside[44],

renders it fluorescent and gives it a strong Raman scattering
efficiency even off resonantly, (Figure 3B).
The characteristic spectral profile of DOX can be easily
identified superimposed on that of the exposed cell lines, and
Figure 4A shows the sucellular uptake of DOX in the A549 and
Calu-1 cell lines, as represented by the characteristic band at 465
cm-1 [21] There is a progressive increase of DOX intracellular
concentration until a plateau is reached after 6-12 hrs exposure
and DOX is seen to accumulate in the nucleolus first, then in the
nucleus and after 24-48 hrs appears in the cytoplasm. The
behaviour is consistent with saturation of nuclear binding sites
after a certain time and any additional drug taken up by cells
accumulates in the cytoplasm.[45, 46] Interestingly, the
accumulation rates are substantially different for the two cell
lines investigated. Simultaneously, the characteristic cellular
features of the subcellular regions can be tracked, as shown in
Figure 4B, for the example of the nucleolus.
A.

B.

Fig. 4. A. Evolution of DOX, represented by the Raman band at
465 cm-1, as a function of time for the A549 and Calu-1 cell line
for each cellular compartment, nucleolus, nucleus and
cytoplasm. B. Evolution of selected DNA and RNA features as
function of time. Intensities are expressed as percentage
according to the maximum value over the three cellular
compartments for each cell line and standard deviation
corresponds to the spectral variations of the Raman band over
the 30 measurements per location. [49, 50]
Multivariate PLSR can be employed to profile the spectrum
of the initial binding interactions of the drug in the subcellular
regions, and the subsequent cellular responses of the cells, in the
plateau regions. There is a striking similarity between the
responses of the different cell-lines to the same drug, and indeed
of the cell lines to drugs of similar mode of action, as
demonstrated for Actinomycin D (Act), a commonly employed
anthracyclic chemotherapeutic agent which is similar in
molecular structure and mode of action to DOX.(47) Comparing
the spectroscopic signatures with the commonly clinically
employed chemotherapeutic agents Cisplatin (Cisp) and
Vincristine (Vinc), there is a remarkable consistency of

spectroscopic signatures of nucleic acids in the nuclear regions,
as shown in Figure 5.(48)

Fig. 5. Regression coefficients obtained by PLSR analysis for the
A549 cell line as a function of drug dose for chemotherapeutic
drugs DOX, Cisp (nucleus) and Vinc (nucleus). [50]
The study of the intracellular localization of DOX demonstrates
that the primary subcellular target is in fact the nucleolus, in
which it interacts strongly with the RNA. Using confocal
microscopy, upon DOX exposure, the nucleoli of the cell appear
dark, however, indicating that the characteristic fluorescence of
DOX is quenched in this dense subcellular region. Therefore,
Raman microspectroscopy sheds light on the cellular
interactions and medicinal chemistry, in situ, which were not
previously known. In the case of the structurally similar ACT, the
cytotoxicologically relevant dose is so low that neither the
fluorescence not the characteristic Raman signature can be
traced at a cellular level. Nevertheless, the initial binding
interactions of the drug within the nucleolus and nucleus of the
cell can be identified, associating them with the similar mode of
action of intercalation as DOX. The timescales of the responses
are significantly slower, however, in both cell lines, which can be
understood in terms of the different intracellular trafficking
processes associated with the bulky polypeptide sidechains of
ACT, compared to DOX. Raman microspectroscopy also
demonstrates that, although Cisp and Vinc are reported to have
different modes of action, as alkylating agents and microtubule
binders, respectively, their Raman signatures evolve from low to
high doses. At doses above their median inhibitory
concentrations, the signatures also exhibit characteristics of
intercalation, as shown DOC and ACT, indicating that they can
have multiple modes of action.[48]
Monitoring the time evolution of drug distribution within the
cell, the spectroscopic signatures of the chemical interaction in
the subcellular regions can be identified, and associated with the
characteristic modes of action of the drug. The signatures are
consistent for drugs of similar modes of action, and thus can be
exploited as a rapid in vitro tool for pre-screening of candidate
drugs and a guide to design strategies for chemotherapeutics.
The subsequent evolution of the spectroscopic signatures can
then be associated with the cellular response pathways. Clear
differences can be seen in the response pathways of the A549
and Calu-1 cell-lines,[47] as evidenced in the univariate analysis
of Figure 4B. PLSR analysis, and correlation with assays to probe
the generation of anti-apoptotic proteins and DNA repair, as
mechanisms of cellular defense, indicate that the differences in
the Raman signatures at the longer time points may be
associated with differing degrees of cellular resistance.[47]

C. Nanotoxicological screening
Most of the strategies that have been proposed for the
investigation of nanomaterials include the combinational use of
toxicity assays, bio-imaging techniques, chemical and
biochemical assays, to obtain information regarding to
metabolic activity, membrane integrities, cellular viability and
cell death mechanisms upon exposure. Cytotoxicity assays have
been widely employed to determine cellular viability and also
cell death rate in vitro. Electron microscopy (EM) and optical
microscopy have been used for the visualisation of
nanomaterials in cells. Confocal Microscopy (CLSM) has also
been used for the visualisation of nanomaterials in cells with the
aid
of
fluorescent
labels.[51-54]
High
Content
Analysis/Screening (HCA/HCS), has opened up new
perspectives for toxicological assessment by providing
multifaceted information with high sensitivity based on
automated imaging of ‘phenotypic assay endpoints’. The
technique has been used for in vitro toxicity assessment, animal
disease models, drug discovery, neurobiology,[55, 56] cell
signalling[57-59] and observation of biochemical changes.[58,
60, 61] However, although conventional techniques have
provided invaluable information regarding the interaction of
nanomaterials with living systems, they remain limited in
various aspects, such as the requirement of multiple labels and
assays, interference of nanomaterials with the assay dyes,[6264] cost and also time required for the investigation. Raman
microspectroscopy offers the potential to holistically screen
uptake mechanisms of, and cellular responses to, nanoparticles,
in vitro.
The correlation between Raman spectral markers of carbon
nanotubes (CNTs) and commonly used cytotoxicity assays has
been studied by Knief et al. [17]. The studies of Dorney et al. [65]
and Keating et al. [66] have shown the localisation of
nanoparticles in cells and the use of multivariate analysis
techniques to obtain more detailed information regarding to
subcellular environment. As an extension of these studies,
Efeoglu et al. demonstrated that the spectroscopic signatures of
the nanoparticle environment in the cytoplasm can be tracked,
as they are processed through endosomes (4hrs), to lysosomes
(12hrs), to the endoplasmic reticulum (24hrs), for the case of 40
nm non-toxic carboxyl-modified PSNPs, as shown in Figure
6.[22] Expressed in terms of the loadings of the principal
component which differentiates the nanoparticle local
environment from control, the signatures demonstrate clear
differences between the biochemical compositions, largely in
terms of lipidic and protein content.
For the case of 100 nm toxic PS-NH2, the biochemical
composition of the cytoplasm as a whole is perturbed by the
cellular responses to exposure, and can be monitored by Raman
microspectroscopy. PS-NH2 are known to elicit acute toxicity as
a result of oxidative stress in the endosomal and lysosomal
pathway [22, 23, 65]. Figure 7 shows the loadings of PCA
obtained from pairwise comparison of particle exposed cells (24
hrs) and corresponding controls. Positive and negative features
of the loadings relate to exposed and unexposed cells,
respectively and the figure summarises spectral markers of
acute toxic response in the cytoplasm, identified by Raman
microspectroscopy. The predominant spectral marker of the
toxic response in the cytoplasm is observed to be the ‘doublet
band’ at 785 and 810 cm-1, which indicates a change in the
cytoplasmic RNA as a result of ROS formation and the doublet
band is observed in particle exposed cells even at low doses

(EC25) and short exposure times (after 4 hrs).[23, 67, 68] The
intensity of the band systematically and progressively changed
as a function of dose and exposure time [23]. The doublet band
was also observed in the biochemical features of Calu-1 cells
following PS-NH2 exposure and progressively changed with
extended exposure times [67]. When a second toxic nanoparticle
model, PAMAM dendrimers, was introduced to the A549 cells, a
similar trend to that for PS-NH2 is observed for the double peak
at 785 and 810 cm-1, which, together with the results obtained
from different cell lines and nanoparticle models, validates the
changes in cytoplasmic RNA as a spectral marker of toxicity [68]..

Fig. 6. Comparison of PCA loadings of 4, 12 and 24 hrs
nanoparticle exposure data sets. Loadings are offset for clarity.
The dotted line represents the zero ‘0’ point for each loading and
an intensity scale of 0±0.1 is used for comparison. [22].
The changes in the doublet band, upon exposure to PS-NH2
and PAMAM, are followed by concomitant and subsequent
changes in the higher end of the fingerprint region, which
provides information about protein (Amide I region) and lipid
damage (1229 and 1438 cm-1). The band at 1438 cm-1, which has
been identified upon PS-NH2 exposure, was also identified after
exposure to PAMAM dendrimers and it has been observed to
provide information regarding to lipotoxicity [23, 67, 69].
Notably, however, especially at extended exposure times, a
significantly different evolution of spectral markers has been
observed for the two different types of toxic nanoparticles,
which can be attributed to different cell death mechanisms.
Although the changes were more significant at long exposure
times, the different response rates of the bands at early time
points also provided information regarding the different cell
death mechanisms. Cell death upon toxicant exposure can occur
in multiple ways, most notably apoptosis and necrosis. The
conventional apoptosis/necrosis assays use colorimetric
identification based on cellular uptake of dyes and give
information related to whether apoptotic or necrotic cell death
has occurred. However, Raman microscopy not only provides
information regarding whether the cell is apoptotic or necrotic,
but also the biochemical path leading to this differentiation
(Figure 8).
Therefore, it can be concluded that Raman microspectroscopy identifies signatures of the initiating toxic
response and subsequent cellular dependent events, as a single,
real-time assay and notably, brings new perspectives to

determination of nanomaterial toxicity by identifying
cytoplasmic RNA as a spectral marker, which is not normally
identified by conventional toxicity assays. Moreover, the doublet
band can be seen as the first strong spectroscopic response of
oxidative stress. Although, it does not measure the ROS directly,
it provides information about the response, which is a ROS
related change in cytoplasmic RNA. The onset of ROS formation
upon nanoparticle exposure has been observed to be within 2-6
hrs [69, 70], and this initial stage of ROS dies away due to the
action of intracellular antioxidants with a similar timescale [69].
In contrast, the doublet band is observed only after 8 hrs
exposure to PS-NH2 and increases further with exposure time.
Adopting the terminology of the Adverse Outcome Pathway
methodology [71], upon exposure to a toxicant, the response
begins with a molecular initiating event (MIE) which induces a
cascade of consequent events. In the current context, the MIE is
identified as the initial oxidative stress caused by the ingestion
of the nanoparticles in exosomes and ultimately results in a
change in cytoplasmic RNA, manifest as changes in the doublet
peak of 785 cm-1 and 810cm-1. The study of Maher et al.[72]
showed that the MIE shows particle dependency and induces
cellular dependant events which can include, for example,
changes in mitochondrial function, activation of caspases, and
release of inflammatory factors. However, conventional and
commonly used cytotoxicity assays use specific markers which
can be defined as ‘endpoints’ and identify the toxicity as a
function of half-maximal effective dose ‘EC50’. Therefore, these
assays remain limited to provide information regarding to
multiple events that occur concomitantly or consecutively inside
the cell. Raman microspectroscopy shows signatures of this
cascade as presence of spectral markers of initiating toxic event
at low doses and short exposure times in the low wavenumber

region (cytoplasmic RNA, indirect ROS), followed by
concomitant changes (Protein and lipid damage as a result of
cellular toxic events) in the higher wavenumber region of the
fingerprint.

Fig. 7. Spectral Markers of acute toxic response in the cytoplasm
of A549 and Calu-1 cells after 24 hrs exposure to PS-NH2 and
PAMAM nanoparticles. Positive and negative features of the
loadings relate to exposed and unexposed cells, respectively. The
750-830 cm-1 and above 1000 cm-1 region are indicated with
highlights. Loadings are offset for clarity. The dotted line
represents the zero ‘0’ point for each loading and intensity scale
of 0±0.05 is used for comparison [23, 67, 68].

Fig. 8. Spectral markers of cell death on cancerous (A) and non-cancerous (B) cell lines and cytotoxicity assays which are found to be
related to the changes of these spectral markers. Loadings are offset for clarity. The dotted line represents the zero ‘0’ point for each
loading and intensity scale of 0±0.05 is used for comparison. [65].

4. Discussion and Conclusions
Technological advances have rendered Raman confocal
microspectroscopy an increasingly routine benchtop laboratory
technique for materials and process analysis. As an optical
technique, it can provide submicron spatial resolution and can
image biological cells and functions at a subcellular level,
providing a wealth of information about the biochemical
makeup, and changes to it due to exogeneous agents. The studies

described herein were designed to explore the reproducibility of
the characteristic spectroscopic signatures associated with
cellular uptake of such agents and the subsequent response
pathways.
The results clearly demonstrate that the subcellular regions
of the cell can be reproducibly differentiated based on their
intrinsic biochemistry, and that the characteristic spectroscopic
profiles are consistent across different cell lines. The subcellular
localisation of chemotherapeutic agents or nanoparticles can be
determined, and characteristic signatures of their initial

chemical interactions can be established. The signatures are
characteristic of the mode of action of the chemotherapeutic
agent or nanoparticle, and, even in cases where the signatures of
the agents themselves cannot be identified (at low doses or for
weak Raman scatterers), these characteristic signatures can act
as evidence of the action of the agent. These initial spectroscopic
signatures can be differentiated from those of the subsequent
cellular response pathways, which can specifically indicate the
mode of cell death or cellular defence mechanisms.
The studies of the model chemotherapeutic agent DOX
demonstrate a clear added value of the technique, as they extend
the current understanding of the mode of action by revealing the
importance of the accumulation in the cell nucleoli, interacting
with the RNA and initiating a cascade of cellular responses. In
fluorescence based confocal microscopy, the nucleoli of DOX
exposed cells appear dark, compared to the strongly fluorescent,
DOX laden surrounding nucleus, and so it is understandable that
such nucleolar based mechanisms have been overlooked, to
date. Raman microspectroscopy reveals, however, that the
nucleolar regions are equally laden with the drug, although it
appears that the fluorescence is quenched due to the binding
interactions in the dense region of the cell.
The label free nature of the technique can thus be of great
benefit for fundamental biochemical and cellular biological
research. It enables, for example, the in situ monitoring of
candidate drugs, of benefit to medicinal chemistry, and the
ability to monitor the processes in live cells can provide a wealth
of high content information for modelling approaches to
pharmacokinetics and (nano) toxicology at a cellular level. The
recent emergence of nonlinear Raman microspectroscopic
techniques adds significantly to the potential in the field, as
video rate, full spectrum analyses of areas of hundreds of
microns have already been reported.[73] Applications in
toxicological screening to guide regulatory processes, in vitro
pre-clinical candidate drug screening to guide synthetic
strategies, and even patient screening for drug
sensitivity/resistance as the basis for companion diagnostics,
can readily be envisaged.
It should be noted, however, that a critical remaining
challenge is that of data-mining the spectral information which
is gathered. Label free, “what you see is what you get”, and the
characteristic spectral signature of a response pathway contains
information of all biomolecules within the sampling focus,
whether they are involved or not. Specific signatures may
dominate, however, and interestingly, the 785-810cm-1, nucleic
acid doublet is prominent in both the studies highlighted here,
albeit respectively in the nuclear regions for the action of drugs,
and in the cytoplasmic region for nanoparticle toxicity, most
likely due to conformational changes in the macromolecules.
Differential signatures compared to control (e.g. PCA loading)
provide the best visualisation of the characteristic changes due
to an exogeneous agent. Regression analyses are appropriate for
monitoring systematic evolutions, and although PLSR has largely
been used in this work, more sophisticated techniques such as
Multiple Component Regression, coupled with Alternating Least
Squares approaches [74] may be more appropriate for response
cascades. In all representations, the responses are spectrally
multivariate, and can have contributions due to conformational
changes, increases or decreases in local concentrations of a
multitude of different biochemical constituents, including lipids,
proteins, carbohydrates and nucleic acids. It is not possible, at
present at least, to quantitatively analyse all these changes with
molecular specificity. Nevertheless, this study indicates that the

spectral signature of combined responses, the “spectralome”, is
reproducible, consistent and translatable from different cell
types and exogenous agents of similar modes of action.
Funding Information. Science Foundation Ireland (11/PI/1108)
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